OVERVIEW

Given the increasing discovery of oncogenic-driven tumors, targeted treatments with novel agents have transformed the outcomes in these patients. Clinical decision making and management therefore have become more complex. There is a need to provide an opportunity for medical oncologists, radiation oncologists, pathologists, allied health professionals, oncology nurses and pharmacists to engage in thoughtful discussions with experts in these fields. In addition, there is emerging data about the biology of these malignancies impacting optimal management of patients with these disorders.

This one-and-a-half-day symposium has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of solid tumors — including lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas and brain tumors — by novel targeted agents and treatment combinations. Updates on evolving molecular-based system therapies will be profiled and discussed.

TARGET AUDIENCE

This educational program is directed toward oncologists, pathologists, radiation oncologists, palliative care staff, oncology and hematology nurses, pharmacists, medical students, residents and fellows in training, research staff and other allied healthcare members interested in the treatment of patients with solid tumor malignancies.

LEARNING OBJECTIVES

Upon completion of this symposium, participants should be better able to:

• Summarize the evolving therapeutic strategies in the treatment of solid tumor malignancies.
• Provide an update of new molecular and targeted treatments being developed for these diseases.
• Discuss the rationale for new targeted diagnostic and therapeutic strategies for lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas and brain tumors.
• Review the role and timing of diagnostic tests, molecular profiling and potential combinations of targeted therapy treatment options.

ACCREDITATION

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been approved for a total of 8.0 credit hours, CE Broker Course #20- , by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.

This activity has also been approved for 8 credit hours for Nurse Practitioners, Nurses, Pharmacists and Techs and Laboratory Personnel. Baptist Health South Florida CE Broker Provider #50-182.

The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts CEs accredited by the ACCME. Individuals are responsible for checking with the AANPCB for further guidelines.

AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC©) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC©). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

For more information please visit the official event page.